BCG Vaccine Reprograms Brain Immunity and Shifts Alzheimer's Biomarkers

Alzheimer's disease remains one of the most feared consequences of aging, and emerging evidence suggests that immune system dysfunction plays a significant role in its development. As the immune system ages, it becomes less effective and may fail to clear harmful protein aggregates like amyloid-β from the brain. This has led researchers to explore immune-modulating strategies as potential early interventions.

Researchers from Massachusetts General Hospital and Harvard Medical School conducted two related open-label clinical trials testing whether BCG — the century-old tuberculosis vaccine known to induce 'trained immunity' — could alter immune function and Alzheimer's-relevant biomarkers in older adults. Twenty-three participants aged 55 or older were enrolled: 12 without Alzheimer's-related pathology and 11 with it. Each received two intradermal BCG vaccinations one month apart and was followed for one year with regular blood draws and cerebrospinal fluid sampling.

The results are striking. BCG induced persistent, trained immunity-like changes in immune cells found in the cerebrospinal fluid, including enhanced innate responsiveness and distinct transcriptional programs. Critically, these changes differed from those seen in the blood, suggesting the central nervous system has its own compartment-specific immune imprinting capacity. In participants without existing Alzheimer's pathology, BCG was associated with decreased amyloid-β in cerebrospinal fluid and increased levels in blood — a pattern consistent with amyloid being cleared from the brain into circulation.

The vaccine was well tolerated across both groups with no unexpected adverse events. These findings are clinically meaningful because they demonstrate, for the first time in humans, that trained immunity can be induced within the central nervous system — a concept previously only theoretical.

However, important caveats apply. The trials were small, open-label, and lacked placebo controls, making it impossible to rule out confounding. Amyloid shifts were seen primarily in those without pre-existing pathology, raising questions about timing and who might benefit most. Larger, randomized controlled trials are essential before any clinical conclusions can be drawn.